Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Moleculin Biotech ( (MBRX) ) has provided an update.
Moleculin Biotech announced significant progress in the development of its drug Annamycin, particularly for relapsed or refractory acute myeloid leukemia (AML). The company has received approval for a pivotal Phase 3 trial, with initial data indicating Annamycin’s potential superiority over existing therapies. The accelerated trial timelines and promising preliminary results could enhance Moleculin’s market position and provide substantial value to stakeholders.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead drug, Annamycin, is designed to circumvent multidrug resistance and reduce cardiotoxicity, with current development targeting relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma.
YTD Price Performance: 1.13%
Average Trading Volume: 51,114
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.71M
For a thorough assessment of MBRX stock, go to TipRanks’ Stock Analysis page.
